<DOC>
	<DOCNO>NCT01361334</DOCNO>
	<brief_summary>Long term disease-free survival ( DFS ) patient acute myeloid leukemia ( AML ) still poor . Recently , so-called `` targeted therapy '' cancer introduce treatment patient AML . This phase II clinical trial explore efficacy , safety , pharmacodynamics tyrosine kinase inhibitor pazopanib patient relapse refractory AML patient AML eligible intensive treatment . Biomarker study include study whether target indeed inhibit whether lead decrease BM angiogenesis . Toxicity assessment include , antileukemic effectiveness study .</brief_summary>
	<brief_title>Pilot Clinical Trial Pazopanib Patients With Relapsed Refractory Acute Myeloid Leukemia ( AML ) Initial Diagnosis When Intensive Treatment Possible</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Subjects must provide write informed consent prior performance studyspecific procedures assessment routinely perform diagnosis monitoring acute myeloid leukemia ( AML ) , subject must willing comply treatment follow assessment procedures 2 . Histologically cytologically confirm diagnosis AML relapse refractory least one induction regimen , patient AML initial diagnosis eligible allogeneic transplant intensive induction chemotherapy , except AML M3 ( acute promyelocytic leukemia ) 3 . Age least 18 year 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤3 5 . Measurable disease burden ( blast BM and/or PB , extramedullary blast [ chloroma ] ) 6 . Able swallow retain oral medication 7 . A life expectancy least 4 week 8 . Adequate contraception method 9 . Adequate organ function define study protocol 1 . Patients valid option intensive chemotherapy and/or stem cell transplantation ( Patients allogeneic stem cell transplant must immunosuppressive agent least 2 week prior study entry Graftversus host disease must resolve Grade ≤2 ) 2 . History cancer accord Investigator might confound assessment endpoint study 3 . Uncontrolled peptic ulcer disease clinically significant gastrointestinal abnormality interfere oral dose unstable serious concurrent condition ( e.g. , active uncontrolled infection ) 4 . Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥140 mmHg diastolic blood pressure ( DBP ) ≥90 mmHg ] . Note : Initiation adjustment antihypertensive medication ( ) permit prior study entry . BP must reassess two occasion separate minimum 1 hour ; occasion , mean ( 3 reading ) SBP / DBP value BP assessment must &lt; 140/90 mmHg order subject eligible study 5 . Prolongation correct QT interval ( QTc ) &gt; 480 millisecond 6 . History one follow cardiovascular condition within past 6 month : cardiac angioplasty stenting , myocardial infarction , unstable angina , symptomatic peripheral vascular disease , class III IV congestive heart failure , define New York Heart Association ( NYHA ) 7 . History cerebrovascular infarction bleeding , pulmonary embolism , untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulant agent least 6 week eligible 8 . Evidence serious active bleeding bleed diathesis ( except bleed petechia due AMLrelated thrombocytopenia treat use platelet transfusion ) . Also , patient know endobronchial lesion and/or lesion infiltrate major pulmonary vessel exclude study due excess risk bleeding . 9 . Prior major surgery trauma within 28 day prior first dose study drug 10 . Treatment investigational agent within 28 day 5 halflives , whichever long prior first dose study drug ( bevacizumab 60 day ) . 11 . Concurrent cytoreductive chemotherapy ( hydroxyurea must discontinue least one day start study medication ) 12 . Known immediate delay hypersensitivity reaction idiosyncrasy pazopanib 13 . Patients psychological , familial , sociological , geographical condition permit compliance protocol 14 . Pregnant lactate actively breastfeed patient 15 . Patients take follow prohibit medication : clarithromycin , telithromycin , troleandomycin ( antibiotic ) ritonavir , indinavir , saquinavir , nelfinavir , amprenavir , lopinavir ( HIV protease inhibitor ) itraconazole , ketoconazole , voriconazole , fluconazole ( antifungal ) nefazodone ( antidepressant )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>( AML M3 )</keyword>
</DOC>